From FDA labels and ClinicalTrials.gov

Are GLP-1s used for type 1 diabetes?

Last updated

If your prescriber prescribes one: the lowest self-pay GLP-1 prices now

  • Lowest compounded tirzepatide on a monthly plan, not FDA-approved

    Collective

    $69/mo + $199/yr membership · about $86 a month over a year with the membership · first order: membership free for the first 21 days, never charged if you cancel before

  • Lowest compounded semaglutide on a monthly plan, not FDA-approved

    Collective

    $59/mo + $199/yr membership · about $76 a month over a year with the membership · first order: membership free for the first 21 days, never charged if you cancel before

  • Lowest FDA-approved, starting dose

    LillyDirect (Eli Lilly)

    from $149/mo

  • Lowest FDA-approved injection, starting dose

    NovoCare (Novo Nordisk)

    $199/fill initially

No current GLP-1 label lists type 1 diabetes as an approved use, so prescribing one for it would be off-label. ADJUST-T1D (Semaglutide): In adults with obesity on automated insulin delivery, 36% on semaglutide met the goal for glucose time in range and at least 5% weight loss against 0% on placebo at 26 weeks. Two severe low blood sugar events in each group. NEJM Evid, 2025 (pubmed.ncbi.nlm.nih.gov/40550013). ClinicalTrials.gov lists 86 trials of these medicines on it: 21 with posted results and 15 recruiting now.

Read from the registry and PubMed every day. The newest update here is Nov 18, 2026.

Published results

What the largest trials on type 1 diabetes found

Each read in the paper's abstract on Nov 6, 2026. Trials differ in who took part and how long they ran.

ADJUST-T1D

Semaglutide · 72 people · Better than the comparison · Placebo-controlled randomized trial

In adults with obesity on automated insulin delivery, 36% on semaglutide met the goal for glucose time in range and at least 5% weight loss against 0% on placebo at 26 weeks. Two severe low blood sugar events in each group.

NEJM Evid, 2025 (pubmed.ncbi.nlm.nih.gov/40550013)

ADJUNCT ONE

Liraglutide · 1,398 people · Mixed · Placebo-controlled randomized trial

HbA1c fell 0.20 points more than placebo at 1.8 mg and weight 4.9 kg more, but symptomatic low blood sugar rose in every liraglutide group, and high blood sugar with ketosis rose at 1.8 mg (rate ratio 2.22).

Diabetes Care, 2016 (pubmed.ncbi.nlm.nih.gov/27506222)

The registry

Trials on type 1 diabetes, by medicine

A trial counts when the registry's conditions or title name this, and some study a related question, such as insulin sensitivity in people with the condition. A registered trial shows a question being asked, not that the answer is yes.

MedicineTrialsPosted resultsRecruiting
Liraglutide38131
Semaglutide1918
Exenatide1770
Tirzepatide805
Dulaglutide301
Mazdutide100
Posted results

What trials on type 1 diabetes reported

Latest phases and largest trials first. Each result is the first primary outcome as its sponsor posted it to the registry, which is not peer review.

TrialMedicinePhasePeopleResult
ADJUNCT ONE™The Efficacy and Safety of Liraglutide as Adjunct Therapy to Insulin in the Treatment of Type 1 DiabetesLiraglutidePhase 31,398Change From Baseline in HbA1c (Glycosylated Haemoglobin) (percentage of glycosylated haemoglobin), Week 0, week 52. Liraglutide 0.6 mg: -0.45; Liraglutide 1.2 mg: -0.50; Liraglutide 1.8 mg: -0.54; Placebo: -0.34.
ADJUNCT TWO™The Efficacy and Safety of Liraglutide Adjunct to Insulin Treatment in Type 1 DiabetesLiraglutidePhase 3835Change From Baseline in Glycosylated Haemoglobin (HbA1c) (Percent (%) glycosylated haemoglobin), Week 0, Week 26. Liraglutide 0.6 mg: -0.23; Liraglutide 1.2 mg: -0.23; Liraglutide 1.8 mg: -0.32; Liraglutide Placebo: 0.01.
NCT01753362Liraglutide In Overweight Patients With Type 1 DiabetesLiraglutidePhase 384HbA1c (percent), 26 weeks, baseline. Placebo: 7.77; Liraglutide: 7.94.
NCT01722266Liraglutide in the Treatment of Type 1 Diabetes MellitusLiraglutidePhase 372Change in Mean Weekly Glucose Concentrations (mg/dl), 12 Weeks. Placebo: 1; Liraglutide 1.8mg: -10; Liraglutide 1.2mg: -10; Liraglutide 0.6 mg: -0.3.
1966Liraglutide in Type 1 DiabetesLiraglutidePhase 369HbA1c (%) (Percent of Hemoglobin (%)), 52 Weeks, week 0. Liraglutide: 7.92; Placebo: 7.48.
NCT02518945Dapagliflozin As Additional Treatment To Liraglutide And Insulin In Patients With Type 1 DiabetesLiraglutidePhase 326Absolute Change After 12 Weeks From Baseline in Mean HbA1c With Addition of Dapagliflozin Compared to Placebo. (% HbA1c), 12 weeks. Placebo: 0; Active Drugs: -0.66.
NCT00679042Islet Transplantation in Type 1 Diabetic Patients Using the University of Illinois at Chicago (UIC) ProtocolExenatidePhase 321On ClinicalTrials.gov (clinicaltrials.gov)
NCT02516657Liraglutide in Adolescents With Type 1 DiabetesLiraglutidePhase 35On ClinicalTrials.gov (clinicaltrials.gov)
NCT01269047Use of Exenatide and Pramlintide to Decrease Post-prandial HyperglycemiaExenatidePhase 437Post-prandial Blood Glucose Concentration in Both Pramlintide and Exenatide Treated Groups in Acute and Chronic Setting, Compared to Insulin Monotherapy in Type 1 Diabetes Mellitus. (mmol/L), 6 months. Acute Pramlintide + Insulin Group: 9.03; Acute Exenatide + Insulin Group: 8.4; Chronic Pramlintide + Insulin Group: 8.0; Chronic Exenatide + Insulin Group: 10.2; Insulin Monotherapy: 10.8.
LIDO52 Week Trial of Liraglutide in Type 1 DiabetesLiraglutidePhase 415Assessment of Changes in Glycemic Control by HbA1c. (percentage of HbA1c), Measure changes in HbA1c at 24 and 52 weeks from baseline. Liraglutide: 0.3; Placebo: 0.2.
NCT01269034New Onset Type 1 Diabetes: Role of ExenatideExenatidePhase 413On ClinicalTrials.gov (clinicaltrials.gov)
NCT02443155A Clinical Proof-of-principle Trial in Adult Subjects With Newly Diagnosed Type 1 Diabetes Mellitus Investigating the Effect of NNC0114-0006 and Liraglutide on Preservation of Beta-cell FunctionLiraglutidePhase 2308Area Under the Concentration-time Curve (AUC) 0-4h of Mixed Meal Tolerance Test (MMTT) Stimulated C-peptide at Week 54 Relative to Baseline (Ratio of AUC), 0 - 4 hours post-dose on week 0 and week 54. NNC0114-0006 + Liraglutide (Experimental): 0.934; NNC0114-0006 (Experimental): 0.783; Liraglutide (Experimental): 0.709; Placebo (Placebo): 0.660.
ADJUST-T1DADJUnct Semaglutide Treatment in Type 1 DiabetesSemaglutidePhase 2115Proportion of Adults With T1D Achieving Composite Outcome (CGM-measured Time in Range (TIR)>70% With Time Below Range (TBR) of <4% and Reduction in Body Weight by 5%) at 26 Weeks in the Semaglutide Group Compared to Placebo Group (Participants), 26 weeks. Semaglutide: 13; Control: 0.
NCT01928329A Phase II Trial to Examine the Effect of Subcutaneous Exenatide (Bydureon®) on Glucose Control in Patients With Type I DiabetesExenatidePhase 279Change From Baseline in HbA1c Levels (mmol/mol), 6 months. Exenatide (Bydureon): -0.12; Placebo: 0.11.
NCT01755416Liraglutide Versus Insulin Mono-therapy in the Closed Loop SettingLiraglutidePhase 218Blood Glucose Measures in Subjects on Closed Loop With Insulin and Liraglutide, Compared to the Closed Loop With Insulin Alone (mg/dl), 0-1500 min. Closed Loop/Insulin: 159.7; Closed Loop/Insulin/Liraglutide: 144.6.
NCT00456300Role of Exenatide in Type 1 DiabetesExenatidePhase 211Mean Plasma Glucose Area Under the Curve (AUC) for Blood Glucose Concentration in the Exenatide 1.25 mcg or Exenatide 2.5 mcg Treated Groups Along With Insulin, Compared to Insulin Alone (mmol*L/min), 0-120 minutes post-dose. Exenatide 1.25 mcg + Insulin: 49; Exenatide 2.5 mcg + Insulin: 44; Insulin Monotherapy: 379.
NCT00566813Islet Transplantation in Type 1 Diabetic Patients Using the Edmonton Protocol of Steroid Free ImmunosuppressionExenatidePhase 1/210Number of Participants With Adverse Events Including Laboratory Abnormalities at the End of Study Participation (participants), 15 months after the last transplant. Islet Cells: 4; Islet Cells + Etanercept + Exenatide: 5.
NCT01206101Efficacy and Safety of Liraglutide in Subjects With Type 1 Diabetes Undergoing Islet Cell TransplantationLiraglutidePhase 23On ClinicalTrials.gov (clinicaltrials.gov)
NCT02962492An Investigation Into the Effect of Dapagliflozin on Ketogenesis in Type 1 DiabetesExenatideNot phased70Change in Beta-hydroxybutyrate Levels in Blood (mM), 12 weeks. Placebo Arm:: -0.23; Dapagliflozin Arm:: 0.63; Exenatide Extended Release Arm:: 0.24; Exenatide Extended Release & Dapagliflozin Arm:: 0.31.
1974Effects of Single Doses of Liraglutide and Dapagliflozin on Ketogenesis in Type 1 DiabetesLiraglutideNot phased43Difference in Ketone Bodies Formation After Single Dose of Liraglutide and Dapagliflozin (mM), 8 hours. Liraglutide 1.8 mg: 0.08; Placebo: 0.25; Dapagliflozin: 0.21.
NCT01856790Effect of Liraglutide on Automated Closed-loop Glucose Control in Type 1 DiabetesLiraglutidePhase 115Peak Post-prandial Venous Glucose Levels (mg/dL), 48 hours. Closed Loop Insulin Delivery: 98; Closed Loop + Liraglutide: 76.
Recruiting now

Trials on type 1 diabetes taking people now

The registry page names each site and who can enroll. Ask your clinician before joining one.

TrialMedicinePhaseExpected to finish
Multifactorial Intervention to Reduce Cardiovascular Disease in Type 1 Diabetes (clinicaltrials.gov/study/NCT06082063)SemaglutidePhase 3Jul 1, 2029
A Clinical Trial Using Tirzepatide to Help Adults With Type 1 Diabetes Automatically Control Their Blood Sugar (clinicaltrials.gov/study/NCT07284511)TirzepatidePhase 2/3Jan 2029
Type 1 Diabetes Impacts of Semaglutide on Cardiovascular Outcomes (clinicaltrials.gov/study/NCT05819138)SemaglutidePhase 3Dec 1, 2027
GIP/GLP-1RA as Adjunctive to Automated Insulin Delivery in Adults With Type 1 Diabetes (clinicaltrials.gov/study/NCT06630585)TirzepatidePhase 3Jun 2026
Lean Mass Changes With Semaglutide in Adults With Type 1 Diabetes and Overweight/Obesity. (clinicaltrials.gov/study/NCT07891156)SemaglutidePhase 2/3Oct 1, 2028
A Clinical Trial to Evaluate The Effects of Semaglutide and Empagliflozin Combined to Automated Insulin Delivery on Diabetes Control in Adults Living With Type 1 Diabetes (clinicaltrials.gov/study/NCT06894784)SemaglutidePhase 3Jan 2027
Alleviating Carbohydrate Counting for Patients with Type-1 Diabetes Using a Closed Loop System with Weekly Subcutaneous Semaglutide (clinicaltrials.gov/study/NCT06387199)SemaglutidePhase 2/3Jan 2027
Tirzepatide Use in People With Obesity and Type 1 Diabetes (clinicaltrials.gov/study/NCT07096908)TirzepatidePhase 4Aug 1, 2028
The Effect of Glycemic Control and of GLP-1 Receptor Agonism on Islet GLP-1 in People With Type 1 and Type 2 Diabetes (clinicaltrials.gov/study/NCT06976619)LiraglutidePhase 2Mar 31, 2029
Trial of Semaglutide for Diabetic Kidney Disease in Type 1 Diabetes (clinicaltrials.gov/study/NCT05822609)SemaglutidePhase 2Dec 2027
Obesity Complicating Type 1 Diabetes: GLP-1 Analogue Anti-obesity Treatment (clinicaltrials.gov/study/NCT06411210)SemaglutidePhase 2Jun 30, 2028
Therapeutic Strategies for Microvascular Dysfunction in Type 1 Diabetes (clinicaltrials.gov/study/NCT05478707)DulaglutidePhase 2Jul 30, 2028
Acute Metabolic Effects of Tirzepatide in Type 1 Diabetes (clinicaltrials.gov/study/NCT06820281)TirzepatidePhase 2Dec 31, 2027
GLP-1Ra Impact on Metabolic Outcomes in Stage 2 T1DM While Receiving Teplizumab (clinicaltrials.gov/study/NCT06338553)SemaglutidePhase 1Mar 2027
A Study of Tirzepatide (LY3298176) in Participants With Type 1 Diabetes Mellitus and Overweight or Obesity (clinicaltrials.gov/study/NCT07803744)TirzepatidePhase 1Dec 2026
From PubMed

Newest papers on GLP-1s and type 1 diabetes

  • A Phase 2, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Acmopatide (CT-868), a Fully Biased GLP-1/GIP Receptor Agonist, in Adults With Type 1 Diabetes and Overweight or Obesity (pubmed.ncbi.nlm.nih.gov/42949535)

    Randomized trial · Diabetes Care · Oct 28, 2026 · Klein KR et al.

  • Effects of Renin-Angiotensin Inhibitors, Sodium-Glucose Cotransporter 2 Inhibitors, Mineralocorticoid Receptor Antagonists and Glucagon-Like Peptide 1 Receptor Agonists on Kidney Outcomes in Patients With Type 1 Diabetes: A Systematic Review and Meta-Analysis (pubmed.ncbi.nlm.nih.gov/42733137)

    Meta-analysis · Diabetes Obes Metab · Sep 13, 2026 · Perry F et al.

  • Efficacy and Safety of Glucagon-Like Peptide-1 Receptor Agonists as Adjuncts to Insulin Therapy in Type 1 Diabetes Mellitus: An Overlap-Informed Umbrella Review (pubmed.ncbi.nlm.nih.gov/42723273)

    Systematic review · Diabetes Obes Metab · Sep 10, 2026 · Lee O et al. · cited by 1

  • Glycaemic Changes After Semaglutide Discontinuation in Adults With Type 1 Diabetes Using Automated Insulin Delivery: Analysis of the ADJUST-T1D Extension Study (pubmed.ncbi.nlm.nih.gov/42675550)

    Randomized trial · Diabetes Obes Metab · Aug 31, 2026 · Montaser E et al. · cited by 1

  • Liraglutide and Βeta-Cell Function in Young Adults With Long-Standing Type 1 Diabetes and Residual C-Peptide: A Blinded, Randomized Controlled Trial (pubmed.ncbi.nlm.nih.gov/42595732)

    Randomized trial · Diabetes Obes Metab · Aug 13, 2026 · Caballero-Corbalán J et al. · cited by 1

  • Insulin, Semaglutide and Dapagliflozin in Adults With Type 1 Diabetes: Design and Methods of Triple Therapy for Type 1 Diabetes (TTT1)-An International Phase 3 Clinical Trial (pubmed.ncbi.nlm.nih.gov/42473259)

    Randomized trial · Diabetes Obes Metab · Jul 19, 2026 · Timmons JG et al. · cited by 1

Listed from Europe PMC as published, newest first. A listing here is not a judgement of a study's quality or a recommendation.

Updated automatically

What changed in trials on type 1 diabetes

  • TrialNew Mazdutide study registered: Efficacy, Safety and Cardiovascular Protection of Mazdutide in Type 1 Diabetes (clinicaltrials.gov/study/NCT07924553)
  • TrialExenatide study now completed (was active, not recruiting): Islet Transplantation in Type 1 Diabetic Patients Using the University of Illinois at Chicago (UIC) Protocol (clinicaltrials.gov/study/NCT00679042)
  • TrialNew Semaglutide study registered: Lean Mass Changes With Semaglutide in Adults With Type 1 Diabetes and Overweight/Obesity. (clinicaltrials.gov/study/NCT07891156)

Written from each source's own record as it changes. Every change on GLPcompare

Questions

GLP-1s and type 1 diabetes: common questions

What did the largest trial on type 1 diabetes find?

ADJUST-T1D (Semaglutide, 72 people): In adults with obesity on automated insulin delivery, 36% on semaglutide met the goal for glucose time in range and at least 5% weight loss against 0% on placebo at 26 weeks. Two severe low blood sugar events in each group.

Is any GLP-1 FDA approved for type 1 diabetes?

Not in any current label we read. A prescriber can still use a medicine off-label, but insurance often limits coverage to approved uses, so ask your plan.

Which GLP-1 has been studied most for type 1 diabetes?

Liraglutide, with 38 registered trials on it, then Semaglutide with 19. More trials do not mean better results: read what each posted.

Can I join a trial of a GLP-1 for type 1 diabetes?

15 trials are recruiting on ClinicalTrials.gov now, listed on this page with their registry pages, which name each site and who can enroll.

Other conditions

GLPcompare is an informational data platform, not a medical provider or pharmacy. Nothing here is medical advice, a diagnosis, or a recommendation to start, stop, or change any treatment. Data is aggregated from public sources and can be incomplete or out of date. Always confirm with a licensed clinician and the current FDA label.